Design, Setting, and Participants
stroke, thromboembolism, diabetes
TRANSIENT ISCHEMIC ATTACK, STROKE, VASCULAR DISEASE, CONGESTIVE HEART FAILURE, THROMBOEMBOLISM, HYPERTENSION, DIABETES
This single-center randomized clinical trial was conducted between 2020 and 2022. Outcomes were assessed prior to their clinic visit and 2 and 90 days after the visit by blinded assessors. Participants included adults with AF and congestive heart failure, hypertension, age at least 75 years (doubled), diabetes, prior stroke or transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years, and sex category scores of 1 or greater presenting for routine care at publicly funded outpatient cardiology clinics within a tertiary teaching hospital. Individuals too unwell to participate or with limited English were excluded. Data were assessed as intention to treat and analyzed from December 2022 to October 2023.